Human Genome Epidemiology Literature Finder
Records 1 - 17 (of 17 Records) |
Query Trace: Myocardial Infarction and CYP2C9[original query] |
---|
Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003 Dec 13 (12): 715-20. Yasar Umit, Bennet Anna M, Eliasson Erik, Lundgren Stefan, Wiman Björn, De Faire Ulf, Rane Ande |
The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenetics and genomics 2007 Jul 17 (7): 473-9. Visser Loes E, van Schaik Ron H N, Jan Danser Alexander H, Hofman Albert, Witteman Jacqueline C M, van Duijn Cornelia M, Uitterlinden André G, Pols Huibert A P, Stricker Bruno H |
Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction. Thrombosis journal 2008 6 7. Haug Kari Bente Foss, Sharikabad Mohammad N, Kringen Marianne K, Narum Sigrid, Sjaatil Stine T, Johansen Per Wiik, Kierulf Peter, Seljeflot Ingebjørg, Arnesen Harald, Brørs O |
Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenetics and genomics 2008 Jun 18 (6): 535-43. Marciante Kristin D, Totah Rheem A, Heckbert Susan R, Smith Nicholas L, Lemaitre Rozenn N, Lumley Thomas, Rice Kenneth M, Hindorff Lucia A, Bis Joshua C, Hartman Brittany, Psaty Bruce |
Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics 2008 Mar 9 (3): 277-88. Kirchheiner Julia, Meineke Ingolf, Fuhr Uwe, Rodríguez-Antona Cristina, Lebedeva Elena, Brockmöller Jürg |
Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals. The pharmacogenomics journal 2009 Oct 9 (5): 327-32. Kaur-Knudsen D, Bojesen S E, Nordestgaard B |
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009 May 119 (19): 2553-60. Mega Jessica L, Close Sandra L, Wiviott Stephen D, Shen Lei, Hockett Richard D, Brandt John T, Walker Joseph R, Antman Elliott M, Macias William L, Braunwald Eugene, Sabatine Marc |
Genetic variance in CYP2C8 and increased risk of myocardial infarction. Pharmacogenetics and genomics 2010 Jul 20 (7): 426-34. Rodenburg Eline M, Visser Loes E, Danser A H Jan, Hofman Albert, van Noord Charlotte, Witteman Jacqueline C M, Uitterlinden André G, Stricker Bruno H |
Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circulation. Cardiovascular genetics 2010 Jun 3 (3): 276-85. Bailey Kristian M, Romaine Simon P R, Jackson Beryl M, Farrin Amanda J, Efthymiou Maria, Barth Julian H, Copeland Joanne, McCormack Terry, Whitehead Andrew, Flather Marcus D, Samani Nilesh J, Nixon Jane, Hall Alistair S, Balmforth Anthony J, |
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. Journal of biomedicine & biotechnology 2011 2011 739751. Kringen Marianne K, Haug Kari Bente Foss, Grimholt Runa M, Stormo Camilla, Narum Sigrid, Opdal Mimi S, Fosen Jan Toralf, Piehler Armin P, Johansen Per W, Seljeflot Ingebjørg, Berg Jens Petter, Brørs O |
Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. Pharmacogenomics 2010 Oct 11 (10): 1359-65. Haschke-Becher Elisabeth, Kirchheiner Julia, Trummer Olivia, Grünbacher Gerda, Kainz Alexander, Boehm Bernhard O, März Winfried, Renner Wilfri |
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC. Cardiovascular interventions 2013 Nov 6 (11): 11. Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G |
Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population. Pharmacological reports : PR 2015 Feb 67 (1): 97-101. Arun Kumar Annan Sudarsan, Kumar Srinivasamurthy Suresh, Umamaheswaran Gurusamy, Kesavan Ramasamy, Balachandar Jayaraman, Adithan Chandrasekar |
Angiotensin-Converting Enzyme Inhibitors' Influence on Antiplatelet Therapy of Clopidogrel in ACS. Clinical laboratory 2016 Oct 62 (10): 1911-1918. Yang Shuo, Cui Chanjuan, Zhang Jie, Qiao R |
The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2018 Apr 34 (2): 328-336. Bedewy Ahmed M L, Sheweita Salah A, Mostafa Mostafa Hasan, Kandil Lamia Sae |
Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study. Scientific reports 2018 1 8 (1): 1229. Joo Hyung Joon, Ahn Sung Gyun, Park Jae Hyoung, Park Ji Young, Hong Soon Jun, Kim Seok-Yeon, Choi WoongGil, Gwon HyeonCheol, Lim Young-Hyo, Kim Weon, Kang Woong Chol, Cho Yun-Hyeong, Kim Yong Hoon, Yoon JungHan, Shin WonYong, Hong Myeong-Ki, Garg Scot, Jang Yangsoo, Lim Do-S |
CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials. American journal of cardiovascular drugs : drugs, devices, and other interventions 2023 2 23 (2): 165-172. van den Broek Wout W A, Mani Nabil, Azzahhafi Jaouad, Ten Berg Jurriën |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source: